Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome (RAPIDA)

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2013 by Maastricht University Medical Center
Sponsor:
Collaborator:
FABPulous B.V.
Information provided by (Responsible Party):
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01826994
First received: April 4, 2013
Last updated: September 12, 2013
Last verified: September 2013

April 4, 2013
September 12, 2013
September 2013
December 2014   (final data collection date for primary outcome measure)
diagnostic value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm [ Time Frame: one and a half year ] [ Designated as safety issue: No ]
Sensitivity, specificity, positive and negative predictive value of point of care heart type fatty acid binding protein testing for acute myocardial infection, alone as well as in combination with a clinical diagnostic algorithm. To determine influence of sex, age, duration of the complaints, and kidney function on clinical performance of heart type fatty acid binding protein testing, subgroup analysis within our study population will be performed
Same as current
Complete list of historical versions of study NCT01826994 on ClinicalTrials.gov Archive Site
  • cost-effectiveness [ Time Frame: one and a half year ] [ Designated as safety issue: No ]
    An economic evaluation by means of an incremental cost-effectiveness ratio will be performed. This evaluation will be performed by determination of the ratio between the difference in costs and the difference in benefits between the two strategies that are observed in this study, being the usual reference policy of the general practitioner and the reference policy that could be created when a determined algorithm combined with point of care heart type fatty acid binding protein testing would be used.
  • definition of an algorithm towards diagnosing acute coronary syndrome and unstable angina [ Time Frame: one and a half year ] [ Designated as safety issue: No ]
    Predictive value of a diagnostic algorithm towards diagnosing acute coronary syndrome and unstable angina is determined, since unstable angina is a condition without rise in biomarkers, but should not be missed by a general practitioner assessing thoracic complaints
Same as current
Not Provided
Not Provided
 
Incremental Value of Point of Care H-FABP Testing in Primary Care Patients Suspected of Acute Coronary Syndrome
Incremental Value of Heart-type Fatty Acid-Binding Protein (H-FABP) in Evaluating Patients Presenting With Symptoms Possibly Matching Acute Coronary Syndrome in Primary Care

Rationale:

Thoracic complaints, possibly due to a cardiac ischemic cause are a diagnostic challenge in general practice. When an underlying ischemic cardiac condition (AMI (acute myocardial infarction), UAP (unstable angina pectoris)) is considered, referral from general practitioner (GP) to a cardiologist has to take place. However, cardiac analysis in 80% of referred patients is negative. To optimize referral decisions of GPs, new and fast diagnostics are needed.

Objective:

To assess the incremental diagnostic value for AMI of a novel rapid PoC H-FABP-test in addition to history taking and physical examination in patients presenting in daily general practice with possible AMI. In addition the cost-effectiveness of the test will be evaluated.

Study design:

Delayed type cross-sectional diagnostic study.

Study population:

Patients presenting to the GP with any new-onset chest complaint, at time of presentation not lasting for more than 24 hours, that is considered to be of possible cardiac origin by the GP.

Intervention:

Point of care Heart Type Fatty Acid Binding Protein test (PoC H-FABP-test), added to usual care. PoC H-FABP-testing, by qualitatively measuring H-FABP in one single drop of blood obtained by finger prick, is added to normal procedures of consultation and referral decision by the GP.

Main study parameters / endpoints:

Sensitivity, specificity, positive and negative predictive value of point of care H-FABP-testing for AMI, alone as well as part of a clinical diagnostic algorithm, in patients with thoracic complaints in general practice. All outcome measures, based on using an algorithm and/or point of care H-FABP-testing, will be compared to regular diagnostic assessment by the GP without using an algorithm and/or point of care H-FABP-testing. Therefore, incremental value of H-FABP-testing and/or a diagnostic algorithm is measured.

Nature and extent of the burden and risks associated with participation, benefit and group relatedness:

Individual participants will experience low risk, since study participation comprehends regular care except for an extra finger prick and possibly collection of one extra venous blood sample. For this low amount of disadvantage, the participant will experience no advantage either. However, results of the study will possibly be useful for similar patients in future.

Not Provided
Interventional
Not Provided
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Diagnostic
  • Acute Coronary Syndrome
  • Angina Pectoris, Unstable
  • Angina Pectoris, Stable
  • Thoracic Diseases
Device: heart type fatty acid binding protein testing
patients
heart type fatty acid binding protein testing
Intervention: Device: heart type fatty acid binding protein testing
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
600
May 2015
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • new-onset chest complaint, considered to be of possible cardiac origin by the general practitioner
  • In case of death of identified cause patients are included as well.

Exclusion Criteria:

  • all attention has to be on acute support for the patient
  • symptoms are present for more than 24 hours
  • oral informed consent is not given during presentation
  • written informed consent is refused afterwards
  • a traumatic cause is present
  • complaints are presented that can be regarded as a recurrence of earlier complaints with clear diagnosis in the past
  • death of unidentified cause.
Both
18 Years and older
No
Contact: Robert Willemsen, MD +31433882302 robert.willemsen@maastrichtuniversity.nl
Belgium,   Netherlands
 
NCT01826994
13-3-015, ABR registry
Yes
Maastricht University Medical Center
Maastricht University Medical Center
FABPulous B.V.
Study Chair: Geert Jan Dinant, professor Maastricht University
Maastricht University Medical Center
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP